| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Avita Medical, Inc.$4.06
-0.35 (-7.94%)
F 4Pipeline Score MedTech · Commercial
Market Cap
140.96 M
EPS
-1.57
P/E Ratio
-
Value Trade
1.00 M
SEC Financials
Q1 2026Dilution Risk
Revenue
19.25 M
R&D Expenses
5.63 M
Operating CF
-10.07 M
Total Assets
51.54 M
Total Liabilities
74.71 M
Equity
-23.17 M
D/E Ratio
12,345
-1.72 %
Week
-6.15 %
1 Month
4.81 %
3 Month
21.16 %
6 Month
-75.52 %
5 Year
-81.68 %
All Time
Cash Data
Cash Position
14.26 M
Monthly Burn
3.36 M
Runway
2.5 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
302.75 K
52 Week Range
3.22 - 7.12
% held by Insiders
3.84 %
% held by Institutions
21.12 %
Enterprise Value
174.82 M
Total Shares
30.77 M
Short %
8.42 %
Float Shares
30.03 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F4
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 5%
Micro Cap (rank 866 of 911)
Percentile RankAvita Medical, Inc. has significant pipeline risk (4/100), but cash runway is a concern.
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
RECELL GO | burn and reconstructive surgeries | — | 2026-06-18 | 17 patients treated at Stoke Mandeville Hospital, uncomplicated donor-site healing, complete graft take, and successful patient discharge without complications. Read More | AVITA Medical Highlights First U.K. Clinical Experience with RECELL GO at British Burn Association Annual Meeting Read More | |
RECELL GO | burn and reconstructive surgeries | — | 2026-06-18 | 17 patients treated at Stoke Mandeville Hospital, uncomplicated donor-site healing, complete graft take, and successful patient discharge without complications. Read More | AVITA Medical Highlights First U.K. Clinical Experience with RECELL GO at British Burn Association Annual Meeting Read More | |
RECELL GO | burn and reconstructive surgeries | — | 2026-06-18 | 17 patients treated at Stoke Mandeville Hospital, uncomplicated donor-site healing, complete graft take, and successful patient discharge without complications. Read More | AVITA Medical Highlights First U.K. Clinical Experience with RECELL GO at British Burn Association Annual Meeting Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RCEL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
RCEL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
RCELAVITA Medical Highlights First U.K. Clinical Experience with RECELL GO at British Burn Association Annual Meeting
AVITA Medical presented the first U.K. clinical experience with RECELL GO at the British Burn Association Annual Meeting. The case series involved 17 patients treated at Stoke Mandeville Hospital, showcasing successful outcomes in burn and reconstructive surgeries. The findings highlight the system's ability to standardize skin cell preparation and enhance operating room efficiency.
Read more →RCEL▼ -8.1%on this news
AVITA Medical to Host Investor Webinar Briefing
AVITA Medical, Inc. is hosting an investor webinar briefing on May 20, 2026, featuring Cary Vance, President and CEO, along with CFO David O'Toole. The event will discuss the company's first quarter 2026 financial results and its advanced acute wound care solutions, including the RECELL platform. Participants can submit questions during the session, which aims to provide insights into the company's commercial progress and priorities for the year.
Read more →RCELAVITA Medical Reports First Quarter 2026 Financial Results
AVITA Medical reported its financial results for the first quarter of 2026, revealing a total revenue of approximately $19.3 million, reflecting a 4% increase from the previous year. The company announced the appointment of Cary Vance as CEO, indicating a strategic leadership change. Despite achieving a gross profit margin of 81.7%, AVITA also reported a net loss of $10.6 million and cash use of $9.9 million for the quarter. Furthermore, AVITA reaffirmed its full-year guidance, expecting revenue growth between 12% to 19% compared to 2025.
Read more →RCELAVITA Medical Names Cary Vance as Chief Executive Officer • Board appoints Cary Vance as President and Chief Executive Officer o Follows successful interim tenure and thorough search process by the Board •
AVITA Medical has appointed Cary Vance as its permanent President and Chief Executive Officer effective immediately, following a successful interim tenure. The Board made this decision after a thorough search process, highlighting Vance's decisive leadership and deep industry experience. Alongside this, Jan Stern Reed has been appointed as Chair of the Board, further emphasizing the company's strategic commitment to growth. Under Vance's leadership, AVITA aims to scale adoption of its products, focusing on improved patient outcomes.
Read more →RCELAVITA Medical Announces TGA Certification in Australia and Medsafe WAND Listing in New Zealand for RECELL GO
AVITA Medical has announced that its RECELL GO system has received regulatory clearances from Australia's TGA and New Zealand's Medsafe. This certification allows for the commercialization of RECELL GO in both countries, promoting standardized and automated skin preparation for burn and trauma treatment. The initial commercial launch is expected to take place shortly through their distribution partner, Revolution Surgical. The innovation promises to enhance clinical efficiency and improve access to treatment for patients in these regions.
Read more →RCEL▼ -7.3%on this news
AVITA Medical to Announce First Quarter 2026 Financial Results
AVITA Medical, a leader in therapeutic acute wound care, will announce its first quarter 2026 financial results on May 14, 2026. The company plans to host a conference call and webcast at 1:30 p.m. Pacific Time to discuss these results and highlight recent business developments. AVITA Medical specializes in wound healing solutions, particularly through its RECELL technology, which is FDA-approved for the treatment of thermal burn and trauma wounds.
Read more →RCEL▼ -7.9%on this news
AVITA Medical Founder Fiona Wood Honored with Lifetime Achievement Award by American Burn Association
AVITA Medical has announced that its founder, Professor Fiona Wood, received the Lifetime Achievement Award from the American Burn Association. This prestigious recognition honors her groundbreaking work in burn care, which includes the development of the RECELL® Spray-On Skin™ technology. Wood's innovative methods have not only advanced treatment practices but also inspired ongoing research and education in the field. Her influence spans over three decades, establishing a legacy that continues to guide current medical practices in burn care.
Read more →RCEL▲ +14.1%on this newsshared move
AVITA Medical Announces Positive Interim Results from Cohealyx Study Demonstrating Accelerated Time to Skin Grafting
AVITA Medical has announced positive interim results from its Cohealyx-I study, highlighting a significant reduction in the mean time to skin grafting for patients with full-thickness wounds. The study demonstrated a mean time of 13.6 days compared to a 33.2 days benchmark, with some patients being grafted as early as 5 days. The statistical superiority of the results supports the product's potential for wider clinical adoption. The full dataset is expected in 2026, and management will hold a webinar to discuss the findings shortly.
Read more →RCELAVITA Medical, Inc. Investigated by the Portnoy Law Firm
AVITA Medical, Inc. is currently under investigation by the Portnoy Law Firm for possible securities fraud, which may lead to a class action lawsuit on behalf of investors. The Company experienced a significant stock price decline of 21% following the release of disappointing second quarter financial results, which revealed issues related to unpaid provider claims impacting product demand. This situation has created uncertainty in the market and affected the utilization of AVITA's RECELL treatment. Investors are encouraged to discuss their legal options with the law firm.
Read more →RCEL▲ +5.9%on this news· ran to +27% by day 3shared move
AVITA Medical Secures 10-Year BARDA Agreement Worth Up to $25.5M to Bolster U.S. Burn Emergency Preparedness
AVITA Medical, Inc. has entered into a 10-year agreement with the Biomedical Advanced Research and Development Authority (BARDA), valued at up to $25.5 million, to bolster U.S. burn emergency preparedness. This contract ensures nationwide access to RECELL products during mass casualty incidents and demonstrates AVITA's commitment to supporting national health resilience. The agreement outlines maintenance for an inventory of RECELL for deployment and requires AVITA to provide logistical support and immediate readiness in emergencies.
Read more →RCELAVITA Medical Showcases Acute Burn and Wound Care Portfolio at ABA 2026, Featuring New Cohealyx Data
AVITA Medical showcased its acute burn and wound care portfolio at the 2026 American Burn Association Annual Meeting, presenting new clinical study data on Cohealyx along with data on RECELL and PermeaDerm. The interim analysis of the Cohealyx multi-center study highlights potential improvements in patient outcomes and reduced hospital length of stay. The company also introduced a new booth experience emphasizing faster recovery for patients. Overall, the event featured numerous presentations reinforcing AVITA's commitment to optimizing wound healing.
Read more →RCELAVITA Medical to participate at the TD Cowen 46th Annual Health Care Conference
AVITA Medical, Inc. is set to participate in the TD Cowen 46th Annual Health Care Conference, taking place in Boston, MA on March 4, 2026. Interim CEO Cary Vance and CFO David O’Toole will lead a presentation and fireside chat during the event. AVITA Medical is known for its RECELL technology, which transforms patient recovery in acute wound care. This event highlights the company’s commitment to advancing its therapeutic solutions.
Read more →RCELAVITA Medical Reports Fourth Quarter and Full Year 2025 Financial Results
AVITA Medical announced its fourth quarter and full year financial results for 2025, reporting total revenues of approximately $71.6 million, an increase of 11% compared to the previous year. However, the company faced challenges with a fourth quarter revenue drop of 4% mainly due to reimbursement issues. Operating expenses were reduced by 9%, and the net loss improved significantly. Additionally, the company secured a new credit facility to support its growth strategy.
Read more →RCELData at 2026 Boswick Burn & Wound Symposium highlight first integrated use of AVITA Medical technologies
AVITA Medical presented data from 19 scientific abstracts at the 2026 Boswick Burn & Wound Symposium, showcasing the integrated use of RECELL, PermeaDerm, and Cohealyx technologies. The findings indicate improved healing and reduced complications in burn and complex wound care. Notably, RECELL demonstrated significant benefits in hospital stay duration and treatment outcomes for older patients.
Read more →RCELAVITA Medical: Pre-J.P. Morgan Update Highlights 2025 Revenue Growth, New Debt Facility, and 2026 Growth Outlook
AVITA Medical has announced preliminary financial results for 2025 and a positive outlook for 2026, highlighting a new $60 million credit facility to support growth. The company aims to shift from stabilization to execution-led growth, with expectations of achieving $15.4 million in revenue in the first quarter of 2026. The upcoming J.P. Morgan Healthcare Conference presentation will further detail their strategy and financial performance.
Read more →RCELAVITA Medical Announces Changes to its Board of Directors
AVITA Medical has appointed Joe Woody as a new non-executive Director, replacing Lou Panaccio, who retired after over a decade of service. Woody's extensive experience in the med-tech sector is expected to enhance the company's growth trajectory. The leadership change is seen as a strategic move to strengthen the board and support long-term value creation.
Read more →RCELAVITA Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference
AVITA Medical announced that CEO Cary Vance will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The event will include a live audio webcast, which will be accessible via the company's website. AVITA Medical is known for its RECELL System, which accelerates wound healing by using a patient's own skin and is FDA-approved for treating burns and trauma wounds. The company's solutions aim to improve clinical outcomes in various markets, including European, Australian, and Japanese markets.
Read more →RCELAVITA Medical to Present at the Piper Sandler 37ᵗʰ Annual Healthcare Conference
AVITA Medical, Inc. will present at the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025. The presentation is scheduled for 8:30 a.m. EST, and management will be available for one-on-one meetings with registered investors. A live audio webcast of the presentation will be accessible on the company's website.
Read more →RCEL▲ +10.9%on this newsshared move
AVITA® Medical Reports Third Quarter 2025 Financial Results
AVITA Medical reported its third quarter 2025 financial results, highlighting a 13% decrease in commercial revenue primarily due to reimbursement challenges. The company achieved CE Mark approval for RECELL GO, enhancing its international presence. Despite a net loss of $13.2 million, AVITA demonstrated improved cash efficiency and reduced operating expenses, indicating a focus on disciplined growth.
Read more →RCELData Presented at the 2025 Southern Region Burn Conference Reinforce RECELL® System as a Standard of Care in Acute Wound Treatment
AVITA Medical presented compelling data at the 2025 Southern Region Burn Conference, reinforcing the RECELL System as a standard of care for acute wound treatment. The findings from a systematic review and a real-world registry analysis highlight the system's effectiveness in reducing donor site burden and accelerating patient recovery. These results underscore the clinical and economic advantages of using RECELL in burn care.
Read more →RCELAVITA Medical to Announce Third Quarter 2025 Financial Results
AVITA Medical, Inc. is scheduled to announce its third quarter financial results for 2025 on November 6, after the close of U.S. financial markets. The announcement will be followed by a conference call and webcast to discuss the results and recent business highlights. The company continues to focus on its transformative wound care solutions, particularly the RECELL System, which has received FDA approval for treating thermal burn and trauma wounds. This event marks an important update for stakeholders as it reflects the company's ongoing progress and performance in the market.
Read more →RCELAVITA Medical Welcomes Support for RECELL® in Burns in Australia
AVITA Medical announced that Australia's Medical Services Advisory Committee (MSAC) has recommended the inclusion of RECELL in the Medicare Benefits Schedule for treating severe acute burn wounds. This endorsement highlights RECELL's clinical effectiveness and its advantages over traditional skin grafting, including reduced hospital stays and improved patient outcomes. The recommendation reflects growing confidence in RECELL's innovative approach to burn care.
Read more →RCEL▼ -25.8%on this news
AVITA Medical Announces CEO Transition
AVITA Medical has appointed Cary Vance as Interim CEO following Jim Corbett's departure. Vance, who has extensive experience in the healthcare sector, will also continue as Chairman of the Board. The company anticipates approximately $17 million in revenue for Q3 2025 and is working with OrbiMed to redefine future covenants. An executive search for a permanent CEO is underway.
Read more →RCELAVITA Medical Announces CEO Transition • Board Chairman Cary Vance appointed Interim CEO • Board member Jan Stern Reed appointed Lead Independent Director • Third quarter 2025 preliminary revenue exp
AVITA Medical announced a leadership transition, appointing Board Chairman Cary Vance as Interim CEO following Jim Corbett's departure. In conjunction, Jan Stern Reed was named Lead Independent Director. The company anticipates its preliminary third-quarter revenue for 2025 to be around $17 million, while also engaging in discussions with OrbiMed to redefine credit agreement covenants. AVITA aims to execute its growth strategy effectively despite the leadership change.
Read more →RCELAVITA MEDICAL INVESTIGATION: Bragar Eagel & Squire, P.C. Reminds AVITA Medical Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Stockholders
Bragar Eagel & Squire, P.C. has initiated an investigation into potential claims against AVITA Medical, Inc. following the company's disclosure of a significant backlog in unpaid provider claims related to its Recell product. This backlog, attributed to delays by Medicare & Medicaid Services in adjudicating claims, has reportedly led to reduced utilization of Recell and financial losses for its stockholders. The investigation may ascertain whether AVITA has violated any federal securities laws amid these developments.
Read more →RCELAVITA REMINDER: Bragar Eagel & Squire, P.C. Reminds AVITA Medical Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Stockholders
Bragar Eagel & Squire, P.C. is investigating potential claims against AVITA Medical, Inc. on behalf of stockholders who may have suffered losses. The investigation follows AVITA's announcement of a backlog in unpaid claims for its Recell procedures, which has led to a drop in utilization and uncertainty among providers. As a result of this news, AVITA's stock price fell by approximately 21% in a single day. The law firm invites affected investors to contact them about their legal rights.
Read more →RCELAVITA (RCEL) INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into AVITA Medical, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating AVITA Medical, Inc. (RCEL) for potential legal claims regarding violations of federal securities laws. This investigation was prompted by the company's report of a substantial backlog of unpaid provider claims for its Recell product, which has impacted financial performance and led to a significant drop in share price. The firm encourages affected investors to contact them for further information on their legal options.
Read more →RCELCMS New Technology Add-On Payment Expands Access to RECELL® for Patients with Non-Burn Acute Wounds
AVITA Medical announced that starting October 1, 2025, hospitals in the U.S. will receive New Technology Add-on Payment (NTAP) reimbursement for using RECELL to treat acute, non-burn wounds. This reimbursement, valid until September 30, 2026, can provide up to $4,875 per case. The NTAP recognizes RECELL's innovative approach to wound treatment, which minimizes donor skin requirements and enhances recovery.
Read more →RCELAVITA Medical, Inc. (RCEL) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
AVITA Medical, Inc. (RCEL) is facing a securities fraud investigation as shareholders who experienced financial losses seek recourse. An investigation by the Law Offices of Howard G. Smith highlights potential violations of federal securities laws due to a significant backlog in unpaid provider claims affecting the company's RECELL procedures. This backlog arose from inadequate pricing and claim adjudication delays by contractors from the Centers for Medicare & Medicaid Services. Consequently, after announcing these issues, Avita's stock saw a dramatic fall of 21%.
Read more →RCELAVITA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating AVITA Medical, Inc. on Behalf of Avita Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating AVITA Medical, Inc. on behalf of its stockholders concerning potential violations of federal securities laws. This comes in light of Avita's recent financial results which revealed a backlog of unpaid provider claims impacting the use of its Recell product. The failure to adjudicate claims in a timely manner has led to decreased demand and uncertainty among providers. Following these disclosures, Avita's stock experienced a significant decline in value.
Read more →RCEL▲ +48.2%on this news
AVITA ALERT: Bragar Eagel & Squire, P.C. is Investigating AVITA Medical, Inc. on Behalf of Avita Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating AVITA Medical, Inc. for potential violations of federal securities laws on behalf of stockholders. The inquiry follows the company's revelation of a significant backlog in unpaid claims related to its Recell product, leading to reduced utilization and impacting financial results. Share prices dropped approximately 21% after the financial issues were disclosed. Investors who suffered losses are encouraged to contact the firm to discuss their legal options.
Read more →RCEL▲ +48.2%on this newsshared move
AVITA Medical Receives CE Mark for RECELL® GO, Enabling Commercialization Across Europe
AVITA Medical has secured the CE Mark for its RECELL GO device, allowing commercialization across Europe. This point-of-care device enables healthcare professionals to prepare a suspension of a patient's skin cells to treat burns and wounds. The CE Mark approval is a significant milestone, facilitating access to advanced treatment options in burn centers across select European countries.
Read more →RCELAVITA Medical, Inc. Investors: Company Investigated by the Portnoy Law Firm
AVITA Medical, Inc. is under investigation by the Portnoy Law Firm for potential securities fraud, following a significant decline in share price. The investigation comes after the company reported a backlog in unpaid claims, which negatively affected the demand for its Recell product. As a result of these issues, the company's stock fell by about 21% on August 8, 2025, prompting investment loss concerns among shareholders. The law firm is encouraging affected investors to come forward to explore legal avenues for recovering losses.
Read more →RCELReal-World Data Shows Significant Reduction in Hospital Stay Using AVITA Medical’s RECELL® System
AVITA Medical reported significant findings from real-world data indicating that its RECELL® System reduces hospital stays by an average of 36% for patients with deep partial thickness burns. The data, presented at the European Burn Association Congress, highlights improved patient outcomes and potential cost savings for healthcare systems. The RECELL System utilizes a patient's own skin to create an autologous skin cell suspension, enhancing recovery efficiency.
Read more →RCELAVITA Medical, Inc. (RCEL) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
AVITA Medical, Inc. is under investigation for potential federal securities law violations after revealing a backlog of unpaid claims that impacted the demand for its wound care product, Recell. Following the release of its second-quarter financial results on August 7, 2025, the company's stock price fell by 21%. The backlog was attributed to delays in pricing adjudication by CMS contractors, causing uncertainty among providers regarding claims payments. Investors who suffered losses are encouraged to contact legal representatives to discuss potential claims.
Read more →RCELAVITA Medical Announces September Investor Conference Participation
AVITA Medical, Inc. announced its participation in three investor conferences scheduled for September 2025. Senior management will host meetings and a live audio webcast featuring CEO Jim Corbett will be available for replay. The company is known for its RECELL System, which optimizes wound healing and is FDA-approved for various applications.
Read more →RCEL▲ +14.8%on this news
AVITA Medical Successfully Completes Australian Equity Raise • Private placement of approximately 17.2 million new CHESS Depositary Interests (“New CDIs”) quoted on the Australian Securities Exchange
AVITA Medical has successfully completed a private placement to raise approximately $15 million via the issuance of around 17.2 million new CHESS Depositary Interests (CDIs) on the Australian Securities Exchange. The funds raised will be utilized for working capital and to support the growth of its therapeutic acute wound care portfolio, with operations expected to continue until free cash flow begins in 2026. The issue price of A$1.32 per CDI represents an 11% discount from the last closing price, indicating potential investor concerns. Settlement of the new CDIs is scheduled for August 19, 2025.
Read more →RCELAVITA Medical Reports Second Quarter 2025 Financial Results, Updates Full-Year Guidance, and Highlights Continued Clinical Innovation
AVITA Medical reported its Q2 2025 financial results, revealing a 21% increase in commercial revenue compared to the previous year, totaling $18.4 million. The company improved its net loss, down to $9.9 million, alongside a reduction in operating expenses. However, the guidance for full-year revenues has been adjusted downward due to a backlog in Medicare payments affecting RECELL utilization. AVITA anticipates recovering demand in the second half of the year as outstanding claims are resolved.
Read more →RCELAVITA Medical Announces Appointment of Michael Tarnoff, MD, FACS, to its Board of Directors and Transition of Board Chair Role to Cary Vance • Dr. Tarnoff brings extensive executive and medical leadership experien
AVITA Medical has appointed Michael Tarnoff, MD, FACS, to its Board of Directors as a non-executive Director to enhance its focus on patient-centric wound-healing technologies. The company also announced that Cary Vance has taken over as Board Chair from Lou Panaccio. Tarnoff's extensive experience from prestigious institutions is expected to bolster AVITA's strategic initiatives. The changes in leadership come as the company aims to expand its influence in the wound care market.
Read more →RCELAVITA Medical to Announce Second Quarter 2025 Financial Results
AVITA Medical, Inc. (NASDAQ: RCEL) has announced that it will report its second quarter 2025 financial results on August 7, 2025, after the U.S. financial markets close. Following the report, the company will host a conference call and webcast at 1:30 p.m. PT to discuss the results and recent business highlights. AVITA Medical is recognized for its innovative therapeutic solutions in acute wound care, particularly the RECELL System, which facilitates skin healing.
Read more →RCELAVITA Medical Highlights Largest Real-World Analysis Demonstrating Reduced Hospital Stay with RECELL
AVITA Medical has presented data showcasing the effectiveness of RECELL technology at the British Burn Association's Annual Meeting. The study, based on registry data from over 6,300 patients, reveals that RECELL reduces the length of hospital stay for burn patients by an average of 6.2 days compared to traditional grafting methods. It also estimates significant cost savings of approximately $300 million over five years due to these reduced stays. This highlights the clinical and economic benefits of RECELL as a transformative solution in acute wound care.
Read more →RCELAVITA Medical Announces First Clinical Publication Demonstrating Accelerated Autograft Readiness with Cohealyx™
AVITA Medical has announced the first clinical publication validating the effectiveness of Cohealyx, a collagen-based dermal matrix, in accelerating autograft readiness for complex wounds. The study found that patients treated with Cohealyx showed faster wound bed vascularization, achieving autograft readiness in just 5 to 10 days, compared to the typical two to four weeks. This advancement in wound management could significantly reduce patient burden and improve clinical outcomes, according to the company's CEO, Jim Corbett. The publication highlights a new standard in wound care with promising results for functional recovery in patients.
Read more →RCELAVITA Medical’s RECELL Platform Recognized for Surgical Innovation in 2025 MedTech Breakthrough Awards
AVITA Medical's RECELL platform has been honored with the 'Best New Technology Solution – Surgical' award at the 2025 MedTech Breakthrough Awards. This accolade recognizes RECELL's innovative approach in treating thermal burn wounds and full-thickness skin defects, impacting over 30,000 patients globally. The platform's efficiency in reducing donor-site pain and its faster recovery times mark significant advancements in wound care. Furthermore, AVITA Medical's Dr. Katie Bush received an award for exceptional innovation in the medical device field, highlighting the company's strong presence in healthcare innovation.
Read more →RCELAVITA Medical’s Acute Wound Care Showcase 2025 Streams Live Today
AVITA Medical is hosting its Acute Wound Care Showcase 2025 virtually, featuring presentations from leading clinicians and patients discussing the benefits of AVITA's technologies. CEO Jim Corbett will highlight the company's innovative approach to acute wound care and key technologies like RECELL, Cohealyx, and PermeaDerm. The event aims to demonstrate the clinical and economic value of AVITA's solutions, with a concluding live Q&A session for attendees. A replay of the event will be available on the company's Investor Relations site following the live stream.
Read more →RCELAVITA Medical Reports First Quarter 2025 Financial Results
AVITA Medical, Inc. reported strong financial results for the first quarter of 2025, with a commercial revenue increase of 67% to $18.5 million. The company launched new products RECELL GO mini and Cohealyx, targeting trauma centers and expanding its market potential. Despite a net loss of $13.9 million, the overall financial health appears robust with a gross profit margin of 84.7%. AVITA has outlined strategic initiatives to drive adoption and growth across its diverse product offerings moving forward.
Read more →RCELAVITA Medical to Host Acute Wound Care Showcase on May 13, 2025
AVITA Medical, a leader in therapeutic acute wound care, announced its first Acute Wound Care Showcase scheduled for May 13, 2025. This virtual event will feature key presentations by the CEO and the Senior Vice President of Scientific and Medical Affairs, offering insights into the company's product portfolio, including RECELL, Cohealyx, and PermeaDerm. The showcase aims to highlight the clinical and economic benefits of AVITA’s technologies, concluding with a live Q&A session. Participants will also have the opportunity to hear directly from patients regarding their experiences with the products.
Read more →RCELAVITA Medical to Announce First Quarter 2025 Financial Results
AVITA Medical, Inc. announced it will report its first quarter 2025 financial results on May 8, 2025, after market closure. A conference call will be held the same day at 1:30 p.m. Pacific Time, where company officials will discuss the financial results and other business highlights. The company is recognized for its innovative therapies in wound care, including the RECELL System, which is pivotal in promoting skin healing across various applications.
Read more →RCEL▲ +13.6%on this news
AVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025
AVITA Medical, Inc. has announced that it will present 16 abstracts at the American Burn Association (ABA) Annual Meeting in Phoenix, Arizona. The presented data will highlight the effectiveness of their innovative wound care technologies, including RECELL, Cohealyx, and PermeaDerm. This presentation represents a significant commitment to advancing burn care and improving clinical outcomes for patients. Notable findings include real-world data supporting RECELL's clinical utility and new insights into the effectiveness of PermeaDerm as a temporary wound coverage solution.
Read more →RCELAVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market Opportunity
AVITA Medical, Inc. has launched Cohealyx, a collagen-based dermal matrix designed to enhance wound healing by facilitating cellular migration and revascularization. This new product complements AVITA's existing offerings and aims to improve clinical outcomes for patients with full-thickness acute wounds. Initial clinical utilization has shown positive results, with integrated wound beds observed within seven days. AVITA is currently conducting a post-market study, the Cohealyx I trial, to further assess the product's effectiveness and patient recovery timelines.
Read more →RCEL▲ +5.6%on this news
AVITA Medical Announces Exclusive Manufacturing and Distribution Agreements with Stedical Scientific
AVITA Medical has announced new exclusive agreements with Stedical Scientific to enhance the manufacturing and distribution of its PermeaDerm Biosynthetic Wound Matrix. The new Contract Manufacturing Agreement will optimize production at AVITA's facility in California to better meet market demand. Additionally, the amended Exclusive Distribution Agreement modifies revenue-sharing terms to ensure a more favorable arrangement for AVITA. These initiatives signify a strengthened collaboration aimed at improving patient outcomes and expanding access to innovative wound care solutions.
Read more →RCELAVITA Medical Reports Fourth Quarter and Full Year 2024 Financial Results
AVITA Medical, a company specializing in therapeutic acute wound care, reported optimistic financial results for the fourth quarter and full year of 2024. The commercial revenue rose significantly by about 30%, and new product approvals from the FDA are set to enhance its market presence. However, the company also reported a substantial increase in net loss and operating expenses, indicating ongoing challenges despite revenue growth. Looking ahead, AVITA projects further revenue growth in 2025 between $100 and $106 million.
Read more →RCELAVITA Medical Updates Expected Fourth Quarter and Full Year 2024 Revenue, Provides 2025 Financial Guidance
AVITA Medical has updated its revenue guidance for the fourth quarter and full year of 2024, anticipating commercial revenue of approximately $18.4 million for Q4, lower than previous estimates. Full-year revenue is expected to be around $64.3 million, reflecting a growth of about 29% year-over-year. The company attributes the lower Q4 revenue to slowed purchasing activity at year-end but forecasts a rebound in 2025 with projected revenues of $100 to $106 million. AVITA continues to expand with new product launches and aims for cash flow break-even and GAAP profitability by Q4 2025.
Read more →RCELAVITA Medical Announces FDA Approval of RECELL GO mini, Optimizing Treatment for Smaller Wounds
AVITA Medical has received FDA approval for its RECELL GO mini, a device tailored for treating smaller wounds up to 480 square centimeters. This approval enhances the existing RECELL GO platform, which previously catered to larger wounds. The mini version aims to expand accessibility for clinicians and address a critical need in the healthcare market. The company plans to roll out the RECELL GO mini in trauma and burn centers starting in early 2025, marking a significant advancement in wound care management.
Read more →RCELAVITA Medical Announces FDA 510(k) Clearance for Cohealyx, Expanding its Addressable Market
AVITA Medical has received FDA 510(k) clearance for Cohealyx, a new collagen-based dermal matrix designed to support tissue integration for full-thickness wounds. This new product aims to significantly expand the company's addressable market in the burns sector, potentially tripling it. Preclinical studies suggest Cohealyx may lead to faster wound healing and better clinical outcomes. Full commercial launch is expected around the second quarter of 2025, supported by forthcoming clinical data to validate its efficacy.
Read more →RCEL▼ -7.7%on this newsshared move
AVITA Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference
AVITA Medical, Inc. (NASDAQ: RCEL) has announced that its CEO, Jim Corbett, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025. The company, which specializes in regenerative medicine, focuses on innovative devices for wound care management. The presentation can be attended live via an audio webcast, with a recording available post-event. AVITA's flagship product, the RECELL System, is designed to transform wound care and has multiple international approvals.
Read more →RCELAVITA Medical Announces Exclusive Distribution Agreement to Expand to Australia and New Zealand
AVITA Medical has entered into an exclusive distribution agreement with Revolution Surgical Pty Ltd to expand its presence in Australia and New Zealand. The deal will allow Revolution Surgical to distribute the RECELL product platform, including the pending RECELL GO product. This agreement is seen as a significant step in reintroducing AVITA’s innovative skin treatment solutions to their original market, aiming to improve patient outcomes in these regions.
Read more →RCELAVITA Medical Reports Third Quarter Financial Results
AVITA Medical, Inc. reported strong financial results for the third quarter of 2024, highlighting a 44% increase in commercial revenue year-over-year, reaching $19.5 million. The company's focus on RECELL GO as a transformative wound care product appears to be paying off, with over 75% of revenue now derived from it. However, AVITA also reported a net loss of $16.2 million and an increase in operating expenses, which raised concerns. The company anticipates upcoming product launches and FDA approvals, positioning itself for continued growth in the wound care sector.
Read more →RCELReimbursement, Economics and Value (REV) Manager – East (remote)
AVITA Medical is seeking a Reimbursement, Economics and Value Manager for the East region, focusing on managing reimbursement and health economics activities. This remote position will support sales teams and customers, acting as an expert in coverage, coding, and reimbursement for AVITA's product portfolio. Candidates with 7-10 years of experience in reimbursement and health economics, particularly in medical devices, are encouraged to apply.
Read more →RCELAVITA Medical to Announce Third Quarter 2024 Financial Results
AVITA Medical, a regenerative medicine company, plans to announce its third quarter 2024 financial results on November 7, 2024. A conference call will follow the announcement to discuss these results and recent business highlights. The company's RECELL System has been recognized internationally for its effectiveness in treating a variety of skin conditions, including burns and vitiligo.
Read more →RCELAVITA Medical to Present at 2024 Cantor Global Healthcare Conference
AVITA Medical, Inc. will be presenting at the 2024 Cantor Global Healthcare Conference on September 18, 2024. David O'Toole, the Chief Financial Officer, will lead the presentation. The company's key product, the RECELL System, is approved for treating thermal burn wounds and skin defects. The technology utilizes a patient's own skin cells to enhance healing outcomes and has received international market approvals.
Read more →RCELAVITA Medical to Participate in Lake Street’s 8th Annual Best Ideas Growth (BIG8) Conference
AVITA Medical, Inc. announced its participation in Lake Street Capital Markets' 8th Annual Best Ideas Growth Conference in New York on September 12, 2024. CEO Jim Corbett will engage in one-on-one meetings with institutional investors throughout the day. The company focuses on regenerative medicine with innovative wound care solutions, including the FDA-approved RECELL System. This participation highlights AVITA's commitment to fostering investor relations and showcasing its advanced medical technologies.
Read more →RCELAVITA Medical Reports Second Quarter Financial Results
AVITA Medical, Inc. reported financial results for the second quarter ended June 30, 2024, revealing a commercial revenue increase of 29% year-over-year, reaching $15.1 million. The company received FDA approval for its RECELL GO product and submitted a supplement for the smaller RECELL GO mini, indicating growth in their treatment capabilities. Despite a net loss escalating to $15.4 million, they project strong future revenue growth and strategic partnerships to enhance their market position. Looking ahead, AVITA anticipates continuing positive momentum with significant revenue increases and product advancements planned for the near term.
Read more →RCEL▼ -11%on this news
AVITA Medical Names Robin VanDenburgh as SVP of U.S. Commercial Sales
AVITA Medical has appointed Robin VanDenburgh as the new Senior Vice President of U.S. Commercial Sales, starting August 6, 2024. With over 25 years of experience in the healthcare industry, her role will focus on driving market growth and enhancing product adoption, particularly for AVITA's RECELL GO system. Her previous experience includes leadership positions at Smith & Nephew and Aureon Biosciences. The company's CEO expressed confidence in her capabilities to accelerate commercial success in the U.S. market.
Read more →RCELAVITA Medical Expands Portfolio with Unique Dermal Matrix to Advance Wound Care Exclusive development and distribution agreement with Regenity Biosciences provides AVITA Medical with the commercialization rights to a uni
AVITA Medical has entered a multi-year exclusive agreement with Regenity Biosciences to develop and distribute a unique collagen-based dermal matrix. This collaboration follows the recent 510(k) clearance by the FDA, allowing AVITA Medical to market and distribute the product in the U.S. and potential international markets. The company plans to conduct multiple clinical studies to assess the synergies between this new product and its existing RECELL technology, with the aim of improving wound care outcomes. The partnership includes financial obligations and revenue-sharing arrangements contingent on clinical success.
Read more →RCEL▲ +5.8%on this news· ran to +25% by day 3
AVITA Medical to Announce Second Quarter 2024 Financial Results
AVITA Medical, Inc. (NASDAQ: RCEL) has announced the date for its second quarter 2024 financial results, set to be reported after U.S. market close on August 8, 2024. The company will also host a conference call and webcast on the same day to discuss the results and recent business highlights. AVITA Medical specializes in regenerative medicine and their RECELL System has received multiple approvals for wound care applications, underscoring their innovative approach in the field.
Read more →RCELAVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary Donna Shiroma retires after distinguished service as General Counsel
AVITA Medical has appointed Nicole Kelsey as Chief Legal and Compliance Officer, effective July 1, 2024, bringing over 20 years of experience. Kelsey has held senior legal positions in various companies, enhancing AVITA's capabilities in regulatory compliance. The announcement also includes the retirement of Donna Shiroma, who served as General Counsel and Corporate Secretary, contributing significantly to the company's growth.
Read more →RCEL▲ +7.6%on this news
AVITA Medical Achieves Milestone with First Case Using RECELL GO
AVITA Medical has announced the successful first use of its RECELL GO™ System at the Joseph M. Still Burn Center, marking a significant milestone for the company. This next-generation device, recently approved by the FDA, utilizes a patient’s own skin to treat burn wounds and skin defects. The device aims to improve patient outcomes by reducing healing time and the need for extensive donor skin. The company plans to roll out RECELL GO to additional burn treatment centers across the U.S. this June.
Read more →RCEL▲ +5.6%on this news
AVITA Medical Announces FDA Approval of
AVITA Medical has received FDA approval for its RECELL GO System, an advanced autologous cell harvesting device designed for the treatment of thermal burn wounds. This next-generation technology offers significant advantages over traditional skin grafting, including improved healing times and reduced requirement for donor skin. The launch of RECELL GO is set to begin in June at leading burn treatment centers in the U.S., marking a significant advancement in wound care management. CEO Jim Corbett emphasized that this approval represents a transformative shift in clinical practices, allowing more patients to benefit from RECELL technology.
Read more →RCEL▲ +5.6%on this news
AVITA Medical Announces FDA Approval of RECELL GO
AVITA Medical has received FDA approval for its RECELL GO system, enhancing the treatment of thermal burn wounds and full-thickness skin defects. This next-generation autologous cell harvesting device offers significant advantages over traditional skin grafting methods, including improved healing, reduced pain, and streamlined operational efficiency for clinicians. The company plans to launch RECELL GO in top burn treatment centers beginning in June 2024. This marks a potentially transformative shift in wound care management.
Read more →RCELAVITA Medical Reports First Quarter Financial Results
AVITA Medical, Inc. reported its first-quarter financial results for 2024, showing a 5.8% increase in commercial revenue. The company launched a new product, PermeaDerm, and remains focused on establishing its RECELL product as a standard care solution in wound management. However, the net loss for the quarter rose to $18.7 million, attributed in part to increased operating expenses. Despite financial challenges, AVITA forecasts positive growth for the upcoming quarter and projects cashflow break even by Q3 2025.
Read more →RCELRegenerative Tissue Specialist – Jacksonville, FL
Avita Medical is seeking a Regenerative Tissue Specialist in Jacksonville, FL, to drive sales and promote its products. The role involves educating medical personnel about Avita's offerings, maintaining customer relationships, and achieving sales targets. The candidate will also be responsible for creating marketing plans and managing sales reporting activities.
Read more →RCELAVITA Medical to Announce First Quarter 2024 Financial Results
AVITA Medical, Inc. (NASDAQ: RCEL) has announced it will report its first quarter 2024 financial results on May 13, 2024, after U.S. market close. A conference call will follow, allowing stakeholders to discuss the results and recent business developments. The RECELL System, a key product in their regenerative medicine portfolio, has received various regulatory approvals, enhancing their market position.
Read more →RCELAVITA Medical Updates Expected First Quarter 2024 Revenue
AVITA Medical has updated its expected revenue for the first quarter of 2024, projecting a decline from previous estimates due to slower account conversions for its newly expanded label. The company expects revenue to fall between $11.0 million and $11.3 million, down from an original guidance of $14.8 million to $15.6 million. Despite the challenges, AVITA remains optimistic for the full year, reaffirming its lower annual revenue guidance of $78.5 million to $84.5 million and emphasizing its growth strategy with new product launches.
Read more →RCELSenior Cost Accountant & Analyst – Valencia
AVITA Medical is seeking a Senior Cost Accountant & Analyst with extensive manufacturing experience. The role involves ensuring accurate inventory valuation, financial reporting, and collaboration with supply chain teams. Candidates should have strong analytical skills and a background in cost accounting, with a minimum of 5-7 years of experience required.
Read more →RCELAssistant Corporate Controller – Valencia
AVITA Medical is seeking an Assistant Corporate Controller in Valencia, California. The role involves preparing financial statements, ensuring compliance with GAAP, and leading the accounting team. Candidates should have experience in public company accounting and a strong understanding of financial processes. The position also emphasizes the importance of information security within the organization.
Read more →RCEL▲ +7.5%on this news
AVITA Medical Submits Response to FDA, Resuming Review Clock for RECELL GO PMA Supplement
AVITA Medical has submitted a response to the FDA regarding its PMA supplement for RECELL GO, resuming the review process under the Breakthrough Devices Program. This response addresses the FDA's inquiry from October 2023 and includes additional data from in-house tests. The review period now has 90 days remaining, with an expected FDA approval by May 30, 2024, allowing for potential product launch the following day. The update reflects AVITA's ongoing commitment to innovate in wound care management.
Read more →RCEL▲ +7.5%on this news
AVITA Medical to Present at TD Cowen 44th Annual Health Care Conference
AVITA Medical, a regenerative medicine company, announced that its CFO, David O'Toole, will present at the TD Cowen 44th Annual Health Care Conference. The presentation is scheduled for March 5, 2024. The company's RECELL System is at the forefront of its product offerings, approved for various treatment applications including thermal burns and vitiligo. The event will include a live audio webcast available on their website, along with a replay for 90 days post-event.
Read more →RCELMedical Science Liaison – Remote (multiple locations)
AVITA Medical is seeking a Medical Science Liaison (MSL) to enhance its clinical and commercial efforts in skin regeneration. The MSL will establish relationships with key opinion leaders, support clinical research initiatives, and translate complex scientific data into accessible information. Interested candidates are encouraged to apply via email.
Read more →RCELDirector/Senior Director, Regulatory Affairs – Irvine or Valencia
AVITA Medical is looking for a Director/Senior Director of Regulatory Affairs to oversee global regulatory activities. The role involves guiding regulatory staff, managing relationships with regulatory authorities, and ensuring compliance with advertising and promotional materials. Candidates should have extensive experience in regulatory affairs, particularly with FDA and European regulations.
Read more →RCELAVITA Medical Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
AVITA Medical (NASDAQ: RCEL) reported significant financial results for Q4 and full-year 2023, with commercial revenue increasing by 50% in the fourth quarter and 46% for the entire year. The company plans to expand its sales organization and launch new products in 2024, including RECELL GO, which is pending FDA approval. Despite the promising revenue growth, AVITA reported a net loss of $7.1 million for the fourth quarter and $35.4 million for the year, attributed to rising operating expenses. The company remains optimistic about achieving profitability by the third quarter of 2025.
Read more →RCELAVITA Medical to Announce Fourth Quarter and Full Year 2023 Financial Results
AVITA Medical, Inc. announced that it will disclose its fourth quarter and full year 2023 financial results after the U.S. markets close on February 22, 2024. The company will also host a conference call to discuss financial results, business progress, and a revenue forecast for 2024. AVITA is aiming for cashflow breakeven and GAAP profitability in a designated quarter of 2025, highlighting its growth trajectory and commitment to regenerative medicine.
Read more →RCELAVITA Medical Announces Exclusive Distribution Agreement with Stedical Scientific
AVITA Medical has announced an exclusive multi-year distribution agreement with Stedical Scientific to commercialize its PermeaDerm Biosynthetic Wound Matrix in the U.S. This partnership aims to leverage the strengths of both companies to expand their reach in the wound care market and improve patient outcomes. The agreement allows AVITA Medical exclusive rights for five years, with potential renewal, and is expected to result in a gross margin of 50% from sales. PermeaDerm is an FDA-cleared matrix designed for various wound treatments, contributing to enhanced healing processes.
Read more →RCELAVITA Medical Announces Preliminary 2023 Financial Highlights, Provides 2024 Financial Guidance and Business Update
AVITA Medical has announced its preliminary financial highlights for the fourth quarter and full year of 2023, showing a significant increase in commercial revenue growth. The company expects Q4 2023 revenue to be about $14.1 million, reflecting a 50% increase year-over-year. Additionally, guidance for 2024 indicates potential revenue growth reaching between $78.5 million to $84.5 million. The completion of patient enrollment for the TONE study, which evaluates treatment outcomes for stable vitiligo, adds a supportive dimension to their business updates.
Read more →RCELAVITA Medical to Present at the 42nd Annual J.P. Morgan Healthcare Conference
AVITA Medical, Inc. (NASDAQ: RCEL) will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024. CEO Jim Corbett will lead the presentation, which highlights the company's advancements in regenerative medicine and the RECELL System, a product designed for skin restoration. A live audio webcast will be available, and a recording will be accessible for 30 days following the event. This presentation aims to enhance the company's market visibility and showcase the effectiveness of its innovative therapies.
Read more →RCELSenior Marketing Manager – Acute Wounds – Valencia
AVITA Medical is seeking a Senior Marketing Manager for Acute Wounds in Valencia, California. This role will focus on expanding the market presence of the RECELL Device in the Burn sector and support commercialization in Soft Tissue Reconstruction. The manager will be responsible for driving growth through various marketing strategies, including digital media and professional conferences.
Read more →RCEL▼ -18.9%on this news
AVITA Medical to Present at the Piper Sandler 35th Annual Healthcare Conference
AVITA Medical, Inc. announced that CEO Jim Corbett will present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023, in New York. The company specializes in regenerative medicine and its RECELL System has been approved for various skin restoration applications. A live webcast of the presentation will be available, enhancing transparency for investors and stakeholders. AVITA Medical continues to seek strategic growth through its innovative therapies.
Read more →RCELAVITA Medical Updates Full Year 2023 Guidance
AVITA Medical has updated its full year 2023 revenue guidance, now projecting approximately $49.5 million to $50.5 million, down from the previous range of $51 million to $53 million. This adjustment is due to slower progress through the Value Analysis Committee processes related to its expanded label for full-thickness skin defects. Despite longer approval timelines, the CEO remains optimistic about the broader clinical involvement and substantial market potential. The revised guidance still reflects significant growth compared to 2022.
Read more →RCELAVITA Medical Reports Third Quarter Financial Results with 51% Revenue Growth over the Same Period the Prior Year
AVITA Medical reported a significant 51% growth in commercial revenue for the third quarter of 2023 compared to the same period in the prior year, reaching $13.5 million. The company also announced plans for international expansion, including a partnership to penetrate European markets. Despite the financial progress, operating expenses increased, leading to a higher net loss of $8.7 million. AVITA is optimistic about reaching profitability by 2025, supported by recent capital securing and ongoing clinical trial activities.
Read more →RCELAVITA Medical Announces Distribution Partnership with PolyMedics Innovations to Expand to Europe
AVITA Medical has entered a distribution agreement with PolyMedics Innovations to expand its market presence in Europe. Under the agreement, PolyMedics will exclusively distribute AVITA's RECELL® product in Germany, Austria, and Switzerland, with potential for broader expansion. This partnership aims to leverage PolyMedics' distribution network and expertise in innovative wound treatments, enhancing the accessibility of AVITA products in the region. Both companies express optimism regarding the collaboration and its potential benefits to patient care.
Read more →RCELAVITA Medical to Announce Third Quarter 2023 Financial Results
AVITA Medical, Inc. has announced that it will release its third quarter 2023 financial results on November 9, 2023. A conference call and webcast will follow to discuss the financial outcomes and recent business highlights. The company specializes in regenerative medicine and has developed the RECELL System, which is approved for treating various skin conditions and has secured multiple international regulatory approvals.
Read more →RCEL▼ -5.6%on this newsshared move
AVITA Medical Announces Preliminary Third Quarter 2023 Financial Highlights and Secures up to $90 million of Non-Dilutive Debt Financing with OrbiMed to Support Growth Initiatives • Preliminary commercial revenue
AVITA Medical announced preliminary financial highlights for Q3 2023, revealing a 50% increase in commercial revenue to $13.5 million compared to the previous year. The company also secured up to $90 million in non-dilutive debt financing through a partnership with OrbiMed to support its strategic growth initiatives. With a strong gross margin of approximately 84.5%, AVITA confirmed its full-year revenue guidance remains unchanged at $51 to $53 million. The financing is expected to facilitate portfolio expansion and strategic execution without the need for immediate equity financing.
Read more →RCELPer Diem Clinical Training Specialist
AVITA Medical is seeking a Per Diem Clinical Training Specialist to enhance the utilization of their RECELL System. The role involves providing clinical support and training to customers, focusing on operating room and aftercare dressing changes. The candidate will work closely with the AVITA Field Sales and Clinical Team to develop educational resources.
Read more →RCELAVITA Medical Receives Best Product Award at the American Association for the Surgery of Trauma
AVITA Medical, Inc. has announced that its RECELL® System received the Best Product award at the American Association for the Surgery of Trauma annual meeting for the second consecutive year. The conference showcased numerous advancements in trauma surgery, and key presentations highlighted the effectiveness of RECELL® in treating full-thickness skin defects. Additionally, pivotal trial results were accepted for publication, solidifying the product's clinical relevance. AVITA also participated in educational workshops aimed at high school students, promoting career paths in trauma surgery.
Read more →RCELAVITA Medical to Present at the Cantor Global Healthcare Conference
AVITA Medical, Inc. announced that its CEO, Jim Corbett, will present at the 2023 Cantor Fitzgerald Global Healthcare Conference on September 26, 2023. The presentation will be accessible through a live webcast on the company's website, indicating AVITA's proactive communication strategy. The company specializes in regenerative medicine, notably through its RECELL System, which has received regulatory approvals for various applications including skin restoration. This participation may enhance investor interest in AVITA's innovative therapies.
Read more →RCELAVITA Medical to Participate in Upcoming Investor Conferences
AVITA Medical, Inc. has announced its participation in two upcoming investor conferences, which highlights its active engagement with the investment community. The Morgan Stanley 21st Annual Global Healthcare Conference will feature a fireside chat on September 13, while the Lake Street Capital Markets 7th Annual Best Ideas Growth Conference is scheduled for September 14. These events will provide opportunities for management to connect with investors through one-on-one and small group meetings.
Read more →RCELAVITA Medical, Inc. First Quarter 2023 Earnings Conference Call
AVITA Medical, Inc. held its First Quarter 2023 Earnings Conference Call on July 29, 2023. The event was led by Jaret Wilson, but no specific financial details or insights were provided in the article. The call likely aimed to discuss the company's performance and outlook for the upcoming quarters.
Read more →RCEL▼ -7.7%on this news
AVITA Medical to Announce Second Quarter 2023 Financial Results
AVITA Medical, a regenerative medicine company, will announce its second quarter 2023 financial results on August 10, 2023, after U.S. market close. A conference call and webcast will follow at 1:30 p.m. Pacific Time to discuss these results and recent business highlights. AVITA's RECELL System is utilized for skin restoration, showing promise in multiple indications including burn treatment and vitiligo.
Read more →RCEL▲ +5.4%on this news
AVITA Medical Submits FDA PMA Supplement for RECELL GO
AVITA Medical has submitted a PMA supplement to the FDA for its RECELL GO device, which innovatively automates the skin sample processing required for Spray-On Skin Cells. This new device eliminates manual management, potentially increasing efficiency and uptake among medical professionals. The submission indicates a commitment to advancing skin restoration technology and improving patient care. With Breakthrough Device designation, the FDA aims to prioritize the review process, and approval is expected by January 2024.
Read more →RCELAVITA Medical Rejoins the Russell 3000 Index
AVITA Medical, Inc. has announced its rejoining of the Russell 3000 Index following the 2023 annual reconstitution. This change, effective June 26, 2023, is anticipated to enhance the company's exposure to an extensive investor base and support its growth initiatives. The Russell indexes are commonly utilized benchmarks for investment strategies, marking a significant milestone for AVITA Medical in its strategic development and recognition in the market.
Read more →RCELFull-Thickness Skin Defects ("FTSD") Market Sizing - June 2023 Update Market Size Additional Market Opportunity (1) (1) Prior to FDA Approval with FDA Approved Expanded Indication of FTSD Traumatic Wounds Traumatic Wound
The June 2023 update on the full-thickness skin defects (FTSD) market reveals a substantial market opportunity, identifying approximately 391,000 eligible procedures across various types of wounds including traumatic, surgical, and chronic conditions. This update is particularly relevant as it coincides with the FDA's approval of expanded indications for FTSD treatments. The report highlights significant types of wounds such as degloving injuries, cancer excisions, and pressure ulcers, underscoring the diverse applications of FTSD therapies. Overall, the findings indicate a promising potential for market growth and increased therapeutic adoption.
Read more →RCELAVITA Medical Announces FDA Approval of RECELL for Skin Repigmentation in Vitiligo Patients
AVITA Medical has received FDA approval for its RECELL System, which is designed for the treatment of vitiligo. This device is the first FDA-approved option to offer a one-time treatment that utilizes a patient's own skin cells to restore pigmentation in stable depigmented areas. The approval was based on a pivotal trial that showed RECELL achieved repigmentation in 36% of treated areas, contributing to an important advancement in skin restoration therapies.
Read more →RCELAVITA Medical Announces Appointment of David O Toole as Chief Financial Officer
AVITA Medical announced the appointment of David O Toole as Chief Financial Officer, effective June 15, 2023. O Toole, with over 30 years of experience, is expected to enhance the company's financial strategies and growth initiatives. His previous roles include CFO at Opiant Pharmaceuticals and Soleno Therapeutics, contributing to his established track record in the biotech industry. The leadership change aims to bolster AVITA Medical's market presence and support the commercialization of their innovative skin restoration technologies.
Read more →RCEL▲ +12.4%on this news
AVITA Medical Announces FDA Approval of RECELL for Treatment of Full-Thickness Skin Defects
AVITA Medical announced that the FDA has approved its RECELL System for treating full-thickness skin defects, marking a significant milestone for the company. This approval broadens the application of RECELL beyond severe burns to include various severe wounds, greatly increasing the market potential. AVITA has also expanded its sales force in preparation for the commercial launch scheduled for July 1, 2023. The RECELL System, which was first approved in 2018 for burn treatment, utilizes a patient’s own skin to produce regenerative cell therapies, potentially improving patient outcomes compared to traditional skin grafting methods.
Read more →RCELAVITA Medical Reports First Quarter Financial Results and Affirms Full Year Guidance
AVITA Medical reported a strong performance in its first quarter of 2023, with revenue growth of 40%, totaling $10.6 million. The company's ongoing expansion of its U.S. field sales organization aims to prepare for the commercial launch of its soft tissue repair indication pending FDA approval in June. However, the increase in total operating expenses to $19.4 million and a net loss of $9.2 million indicate financial challenges ahead, despite a positive revenue trajectory.
Read more →RCELAVITA Medical to Announce First Quarter 2023 Financial Results Valencia, Calif.
AVITA Medical is set to report its first quarter 2023 financial results on May 11, 2023, after U.S. market close. The company will also host a conference call and webcast to discuss its financial outcomes and recent business highlights. AVITA Medical is recognized for its RECELL System, a technology for skin restoration approved by the FDA and used globally. The RECELL System has shown its benefits in treating severe burns and is rapidly gaining traction in various international markets.
Read more →RCELAVITA Medical Announces Update to Automation Device
AVITA Medical has announced that its automated device, RECELL GO, continues to hold FDA Breakthrough Device designation for treating acute wounds. The new device is designed to automate cell disaggregation, which the company believes will enhance growth by reducing training needs and easing the burden on healthcare staff. A Premarket Approval (PMA) supplement for RECELL GO is planned for submission to the FDA by June 30, 2023, with an expected interactive review leading to approval by January 2024.
Read more →RCELAVITA Medical Appoints New Non-Executive Member to the Board of Directors
AVITA Medical has appointed Robert McNamara to its Board of Directors, bringing over 25 years of experience in the medical device industry. His extensive background in operations and financial management is expected to bolster the company's growth objectives. The RECELL System, AVITA's flagship product, continues to demonstrate positive outcomes in treating severe burns and shows promise for multiple therapeutic indications, enhancing the company's overall value and market position.
Read more →RCELCertain statements in this presentation and the accompanying oral commentary are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statemen
AVITA Medical's presentation outlines forward-looking statements regarding its technology and development strategies. The company reported significant growth in its RECELL system's commercial revenue, highlighting a 37% increase in Q4 2022 compared to the previous year. Furthermore, recent FDA breakthrough designations for RECELL in soft tissue repair and vitiligo may expand its application. However, AVITA acknowledges various risks and uncertainties that could impact future outcomes, including clinical trial challenges and market acceptance.
Read more →RCELAVITA Medical to Present at the TD Cowen 43rd Annual Health Care Conference
AVITA Medical, Inc. will be presenting at the TD Cowen 43rd Annual Health Care Conference in Boston, scheduled for March 7, 2023. Jim Corbett, the CEO, is set to showcase the company's advancements in regenerative medicine, particularly focusing on its RECELL System that allows for better treatment of skin restoration. The RECELL System has been recognized for its efficacy in treating burns and other skin conditions, with a focus on utilizing a patient's own skin for healing. A live audio webcast of the presentation will be available on the company's website.
Read more →RCELAVITA Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance
AVITA Medical, Inc. reported strong financial results for Q4 and full-year 2022, showing a significant increase in revenue while ending the year with no debt and significant cash resources. The company has received multiple FDA designations for its RECELL® System and has submitted applications for new indications in soft tissue repair and vitiligo. Looking ahead, AVITA expects substantial revenue growth in 2023 driven by anticipated FDA approvals and a strategic expansion of their sales team. However, despite these positives, the company continues to face challenges with rising operating expenses and a net loss that has slightly increased year-over-year.
Read more →RCELAVITA Medical to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide 2023 Financial Guidance Valencia, Calif., and
AVITA Medical, Inc. (NASDAQ: RCEL) announced that it will report its fourth quarter and full year 2022 financial results on February 23, 2023. The company, known for its regenerative medicine products, will also provide guidance for 2023 during a conference call. The RECELL System, its flagship product, has shown significant progress in clinical outcomes for severe burn treatments. The results are expected to highlight the company's performance and strategic direction moving forward.
Read more →RCELAVITA Medical Announces Management Changes and Fourth Quarter 2022 Earnings Conference Call VALENCIA, Calif., and
AVITA Medical announced changes to its management structure, including the departure of Chief Financial Officer Michael Holder and an interim appointment of Sean Ekins. These changes are part of a strategy to enhance operational efficiency under the leadership of new CEO James Corbett. The company aims to accelerate growth through the commercialization of its RECELL System, which is already approved for treating burn wounds, enhancing clinical outcomes, and offering cost savings. A conference call is scheduled for February 23, 2023, to discuss the fourth quarter financial results and business updates.
Read more →RCELAVITA Medical Submits FDA PMA Application to Expand Indication to Vitiligo VALENCIA, Calif., and
AVITA Medical Submits FDA PMA Application to Expand Indication to Vitiligo VALENCIA, Calif., and MELBOURNE, Australia, December 19, 2022 (GLOBE NEWSWIRE) AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization
Read more →RCELMr. Lou Panaccio, Chairman of the Board of AVITA Medical, Inc. Call To Order Brief Company Overview Welcome Outside the U.S. please call: +1 (781) 575-2748 In the U.S. please call toll free: +1 (888) 724-2416 Experiencin
Annual Meeting of Stockholders DECEMBER 12, 2022 (PST) / DECEMBER 13, 2022 (AEDT) Exhibit 99.1 Mr. Lou Panaccio, Chairman of the Board of AVITA Medical, Inc. Call To Order Brief Company Overview Welcome Outside the U.S. please call: +1 (781) 575-2748 In the U.S. please call
Read more →RCEL▲ +7.8%on this newsshared move
AVITA Medical Announces Results of 2022 Annual Meeting of Stockholders
VALENCIA, Calif. and MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin
Read more →RCELAVITA Medical Submits FDA PMA Supplement to Further Expand Indication to Soft Tissue Repair
VALENCIA, Calif., and MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restorati
Read more →RCELAVITA Medical to Present at the Piper Sandler 34th Annual Healthcare Conference
VALENCIA, Calif., and MELBOURNE, Australia, Nov. 21, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restorati
Read more →RCEL▲ +12.7%on this news· ran to +39% by day 3
AVITA Medical Reports Third Quarter 2022 Financial Results
AVITA Medical Reports Third Quarter 2022 Financial Results VALENCIA, Calif. and MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the Company ), a regenerative medicine company leading the development and commercialization of fir
Read more →RCELAVITA Medical Announces Achievement of Co-Primary Endpoints in Updated Analysis of Pivotal Trial of RECELL System for Soft Tissue Repair
VALENCIA, Calif. and MELBOURNE, Australia, Nov. 09, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoratio
Read more →RCEL▲ +5.1%on this news· ran to +16% by day 3shared move
AVITA Medical Announces FDA Breakthrough Device Designations for the RECELL System
VALENCIA, Calif. and MELBOURNE, Australia, Nov. 03, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoratio
Read more →RCELASX/News Release AVITA Medical Announces FDA Breakthrough Device Designations for the RECELL System Valencia, Calif.
AVITA Medical Announces FDA Breakthrough Device Designations for the RECELL System Valencia, Calif., November 3, 2022 and MELBOURNE, Australia, November 4 2022 (GLOBE AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and comme
Read more →RCELAVITA Medical to Announce Third Quarter 2022 Financial Results
VALENCIA, Calif. and MELBOURNE, Australia, Oct. 20, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoratio
Read more →RCEL▲ +7%on this news
AVITA Medical Appoints Industry Leader James Corbett as Chief Executive Officer
AVITA Medical Appoints Industry Leader James Corbett as Chief Executive Officer VALENCIA, Calif. and MELBOURNE, Australia, Sept. 28, 2022 (GLOBE NEWSWIRE) AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization
Read more →RCEL▲ +7.3%on this news
AVITA Medical Achieves Positive Topline Pivotal Trial Results for Treatment of Stable Vitiligo Using the RECELL System The study achieved its primary effectiveness endpoint of super-superiority AVITA Medical continues to
AVITA Medical Achieves Positive Topline Pivotal Trial Results for Treatment of Stable Vitiligo Using the VALENCIA, Calif. 12 SEPTEMBER 2022 and MELBOURNE, Australia, 13 SEPTEMBER 2022 AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company leadin
Read more →RCELRECELL System Insurance Coverage Begins in Japan for Treatment of Acute Burns Reimbursement in Japan will be similar to that of pricing in the United States VALENCIA, Calif. and MELBOURNE, Australia, 01 September 2022 AV
RECELL System Insurance Coverage Begins in Japan for Treatment of Acute Burns Reimbursement in Japan will be similar to that of pricing in the United States VALENCIA, Calif. and MELBOURNE, Australia, 01 September 2022 AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerativ
Read more →RCELAVITA Medical Announces Topline Results from Pivotal Trial in Patients with Soft-Tissue Injuries using the RECELL System
AVITA Medical plans to submit PMA supplement for this new indication to FDA by the end of 2022 VALENCIA, Calif. and MELBOURNE, Australia, Aug. 11, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company that is developing
Read more →RCELAVITA Medical Reports Second Quarter 2022 Financial Results
AVITA Medical Reports Second Quarter 2022 Financial Results VALENCIA, California, August 11, 2022 and MELBOURNE, Australia, August 12, 2022 AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the Company ), a regenerative medicine company that is developing and commercializing a tech
Read more →RCELAVITA Medical to Announce Second Quarter 2022 Financial Results
VALENCIA, Calif., and MELBOURNE, Australia, July 25, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for mult
Read more →RCELASX/News Release AVITA MEDICAL, INC. Substantial holder notice VALENCIA, Calif., USA, and MELBOURNE, Australia 22 July 2022 : AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) ( Company ) advises that it is aware of changes to
Substantial holder notice Calif., USA, and MELBOURNE, Australia 22 July 2022: AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (Company) advises that it is aware of changes to its substantial holders that were previously disclosed to the market. Set out below are details, to the bes
Read more →RCEL▲ +9.9%on this news
AVITA Medical Reports First Quarter 2022 Financial Results
AVITA Medical Reports First Quarter 2022 Financial Results VALENCIA, Calif. and MELBOURNE, Australia, May 12, 2022 (GLOBE NEWSWIRE) AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the Company ), a regenerative medicine company that is developing and commercializing a technology p
Read more →RCELRECELL System to be Highlighted at Upcoming Music City SCALE Multidisciplinary Dermatology Meeting VALENCIA, Calif. and MELBOURNE, Australia, 09 MAY 2022 AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenera
RECELL System to be Highlighted at Upcoming Multidisciplinary Dermatology Meeting VALENCIA, Calif. and MELBOURNE, Australia, 09 MAY 2022 AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company that is developing and commercializing a technology
Read more →RCELAVITA Medical to Announce First Quarter 2022 Financial Results
VALENCIA, Calif. and MELBOURNE, Australia, April 28, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for mult
Read more →RCELASX/News Release AVITA Medical to Announce First Quarter 2022 Financial Results Valencia, Calif., and
AVITA Medical to Announce First Quarter 2022 Financial Results Valencia, Calif., and MELBOURNE, Australia, April 28, 2022 (GLOBE NEWSWIRE) AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform
Read more →RCELAvita Medical, Inc. Announces Resignation of Louis Drapeau from Board of Directors VALENCIA, Calif. 21 April 2022 and MELBOURNE, Australia, 22 April 2022 AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenera
Avita Medical, Inc. Announces Resignation of Louis Drapeau from Board of Directors VALENCIA, Calif. 21 April 2022 and MELBOURNE, Australia, 22 April 2022 AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company that is developing and commercializi
Read more →RCELRECELL System Data to be Presented at the American Burn Association Annual Meeting
RECELL System Data to be Presented at the American Burn Association Annual Meeting 15 presentations will highlight the use of the platform for the treatment of pediatric and adult burn wounds VALENCIA, Calif. and MELBOURNE, Australia, April 04, 2022 (GLOBE NEWSWIRE) AVITA Med
Read more →RCELAVITA Medical Announces Modification of BARDA Contract to Advance Development of RECELL System in Soft Tissue Reconstruction
AVITA Medical Announces Modification of BARDA Contract to Advance Development of RECELL System in Soft Tissue Reconstruction will support completion of the ongoing pivotal clinical trial VALENCIA, Calif. and MELBOURNE, Australia, March 21, 2022 (GLOBE NEWSWIRE) AVITA Medical,
Read more →RCELFebruary 2022 NASDAQ: RCEL ASX: AVH Copyright 2022 AVITA Medical. All Rights Reserved. Legal Disclaimers Certain statements in this presentation and the accompanying oral commentary are "forward-looking statements" withi
Legal Disclaimers Certain statements in this presentation and the accompanying oral commentary are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this
Read more →RCELAvita Medical, Inc. Signs Agreement with Premier, Inc. to Supply the RECELL System to Hospitals and Health Systems Across the U.S. Agreement ensures timely access to the RECELL System for the approximately 4,440 U.S. hos
Avita Medical, Inc. Signs Agreement with Premier, Inc. to Supply the RECELL System to Hospitals and Health Systems Across the U.S. timely access to the RECELL System for the approximately 4,440 U.S. hospitals and health systems in Premier s network VALENCIA, Calif. and MELBOURN
Read more →RCEL▼ -5.8%on this news· ran to -17% by day 3shared move
Avita Medical, Inc. Signs Agreement with Premier, Inc. to Supply the RECELL System to Hospitals and Health Systems Across the U.S.
VALENCIA, Calif. and MELBOURNE, Australia, March 02, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for mult
Read more →RCEL▲ +14.9%on this newsshared move
AVITA Medical Reports Quarter Ending
AVITA Medical Reports Quarter Ending December 31, 2021, and Transition Period July 1, 2021, to December 31, 2021, Financial Results VALENCIA, Calif, February 28, 2022 and MELBOURNE, Australia, March 1, 2022 AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (the Company ), a regenera
Read more →RCELAVITA Medical Reports Quarter Ending December 31, 2021, and Transition Period July 1, 2021, to December 31, 2021, Financial Results
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 28, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (the “Company”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restor
Read more →RCELThe RECELL System Receives PMDA Approval in Japan and AVITA Medical will Commercialize in Partnership with COSMOTEC, an M3 Group Company VALENCIA, Calif. and MELBOURNE, Australia, 23 February 2022 AVITA Medical, Inc. (NA
The RECELL System Receives PMDA Approval in Japan and AVITA Medical will Commercialize in Partnership with COSMOTEC, an M3 Group Company VALENCIA, Calif. and MELBOURNE, Australia, 23 February 2022 AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company th
Read more →RCELAVITA Medical to Present at the Cowen 42nd Annual Health Care Conference
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multi
Read more →RCELAVITA Medical Announces FDA Approval of New RECELL System with Improved Ease of Use System enhanced in response to clinician workflow and usability feedback; new system simplifies process United States product launch pla
AVITA Medical Announces FDA Approval of New RECELL System with Improved Ease of Use System enhanced in response to clinician workflow and usability feedback; new system simplifies process United States product launch planned for Q2 2022 VALENCIA, Calif. and MELBOURNE, Austra
Read more →RCELAVITA Medical to Announce Transition Period July 1, 2021 to December 31, 2021 Financial Results
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 15, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multi
Read more →RCELAVITA Medical to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
AVITA Medical to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference VALENCIA, Calif. and MELBOURNE, Australia, Feb. 02, 2022 (GLOBE NEWSWIRE) AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing an
Read more →RCELAVITA Medical Announces Preliminary Unaudited Results for the Quarter ended December 31, 2021
VALENCIA, Calif. and MELBOURNE, Australia., Jan. 10, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (the “Company”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin resto
Read more →RCELAVITA Medical Completes Enrollment in Pivotal Trial Evaluating the RECELL System for Soft-Tissue Reconstruction
VALENCIA, Calif. and MELBOURNE, Australia, Jan. 06, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multi
Read more →RCELAVITA Medical Establishes Proof of Concept for Novel Treatments Using Genetically-Modified Skin Cells
VALENCIA, Calif. and MELBOURNE, Australia, Jan. 06, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multi
Read more →RCELAVITA Medical Announces Preliminary Unaudited Results for the Quarter ended
AVITA Medical Announces Preliminary Unaudited Results for the Quarter ended December 31, 2021 VALENCIA, Calif, January 10, 2022 and MELBOURNE, Australia, January 11, 2022 AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (the Company ), a regenerative medicine company that is develop
Read more →RCELAVITA Medical, Inc.: Results of 2021 Annual Meeting of Shareholders
AVITA Medical, Inc.: Results of 2021 Annual Meeting of Shareholders December 22, 2021 (United States) / December 23, 2021 (Australia) VALENCIA, Calif. and MELBOURNE, Australia, December 22, 2021 (United States) / December 23, 2021 (Australia) (GLOBE NEWSWIRE) AVITA Medical, In
Read more →RCEL▲ +5.5%on this news
AVITA Medical Completes Enrollment in Pivotal Trial Evaluating the RECELL System for Repigmentation of Stable Vitiligo
VALENCIA, Calif. and MELBOURNE, Australia, Dec. 15, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multi
Read more →RCEL▼ -5.1%on this newsshared move
AVITA MEDICAL, INC. ANNOUNCES ADJOURNMENT OF 2021 ANNUAL STOCKHOLDER MEETING VALENCIA, Calif. and
AVITA MEDICAL, INC. ANNOUNCES ADJOURNMENT OF 2021 ANNUAL STOCKHOLDER MEETING VALENCIA, Calif. and MELBOURNE, Australia December 14, 2021 (United States) / December 15, 2021 (Australia) AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is develop
Read more →RCELAVITA Medical to Present at Upcoming Investor Conferences
VALENCIA, Calif., and MELBOURNE, Australia, Nov. 16, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for mult
Read more →RCELAVITA Medical Reports First Fiscal Quarter 2022 Financial Results
AVITA Medical Reports First Fiscal Quarter 2022 Financial Results VALENCIA, Calif, November 8, 2021 and MELBOURNE, Australia, November 9, 2021 AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (the Company ), a regenerative medicine company that is developing and commercializing a te
Read more →RCEL▲ +7.1%on this newsshared move
AVITA Medical Announces Expanded Medicare Reimbursement to Outpatient Hospital and Ambulatory Surgical Centers
VALENCIA, Calif. and MELBOURNE, Australia, Nov. 03, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multi
Read more →RCELAVITA Medical to Announce Fiscal First Quarter 2022 Financial Results
VALENCIA, Calif. and MELBOURNE, Australia, Oct. 25, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multi
Read more →RCELAVITA Medical to Present at the 2021 Cantor Virtual Global Healthcare Conference
VALENCIA, Calif., and MELBOURNE, Australia, Sept. 13, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for mul
Read more →RCELAVITA Medical to Participate at the Lake Street 2021 BIG5 Conference
VALENCIA, Calif., and MELBOURNE, Australia, Aug. 31, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for mult
Read more →RCELAVITA Medical Reports Fourth Quarter and Fiscal Year 2021 Financial Results
AVITA Medical Reports Fourth Quarter and Fiscal Year 2021 Financial VALENCIA, Calif, August 26, 2021 and MELBOURNE, Australia, August 27, 2021 AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (Company), a regenerative medicine company that is developing and commercializing a technol
Read more →RCELAVITA Medical to Announce Fiscal Fourth Quarter 2021 Financial Results
AVITA Medical to Announce Fiscal Fourth Quarter 2021 Financial Results VALENCIA, Calif., and MELBOURNE, Australia, Aug. 12, 2021 (GLOBE NEWSWIRE) AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology pl
Read more →RCELAVITA Medical Announces Inclusion in the Russell 3000 Index VALENCIA, Calif., USA
AVITA Medical Announces Inclusion in the Russell 3000 Index VALENCIA, Calif., USA, June 29, 2021 and MELBOURNE, Australia, June 30, 2021 (GLOBE NEWSWIRE) AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a techn
Read more →RCELAVITA Medical Announces Preliminary Fourth Quarter 2021 Financial Results VALENCIA, Calif., USA
AVITA Medical Announces Preliminary Fourth Quarter 2021 Financial Results VALENCIA, Calif., USA, June 15, 2021, and MELBOURNE, Australia, June 16, 2021 (GLOBE NEWSWIRE) AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commerci
Read more →RCELAVITA MEDICAL, INC. APPOINTS TWO NEW NON-EXECUTIVE
AVITA MEDICAL, INC. APPOINTS TWO NEW NON-EXECUTIVE MEMBERS TO THE BOARD OF DIRECTORS VALENCIA, CA, June 1, 2021 and MELBOURNE, Australia, June 2, 2021 AVITA Medical, Inc. (Nasdaq: RCEL; ASX: AVH) ( AVITA Medical ), a regenerative medicine company that is developing and commerc
Read more →RCELAVITA Medical, Inc. Appoints Two New Non-Executive Members to the Board of Directors
VALENCIA, Calif. and MELBOURNE, Australia, June 01, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (Nasdaq: RCEL; ASX: AVH) (“AVITA Medical”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin res
Read more →RCELAVITA Medical Reports Third Quarter 2021 Financial Results
AVITA Medical Reports Third Quarter 2021 Financial Results VALENCIA, Calif, May 13, 2021 and MELBOURNE, Australia, May 14, 2021 AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform th
Read more →RCELAVITA Medical to Announce Fiscal Third Quarter 2021 Financial Results
VALENCIA, Calif. and MELBOURNE, Australia, April 29, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoratio
Read more →RCELAVITA Medical, Inc. Names Michael Holder as Chief Financial Officer
AVITA Medical, Inc. Names Michael Holder as Chief Financial Officer VALENCIA, Calif. and MELBOURNE, Australia, March 22, 2021 (GLOBE NEWSWIRE) AVITA Medical, Inc. (Nasdaq: RCEL; ASX: AVH) ( AVITA Medical ), a regenerative medicine company that is developing and commercializing
Read more →RCELAVITA MEDICAL, INC. ANNOUNCES CLOSING OF OFFERING OF 3,214,250
AVITA MEDICAL, INC. ANNOUNCES CLOSING OF OFFERING OF 3,214,250 SHARES OF COMMON STOCK VALENCIA, CA, March 1, 2021 and MELBOURNE, Australia, March 2, 2021 AVITA Medical, Inc. (Nasdaq: RCEL; ASX: AVH) ( AVITA Medical ), a regenerative medicine company that is developing and comme
Read more →RCELAVITA Medical, Inc. Announces Pricing of Its Public Offering of Common Stock
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 25, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (Nasdaq: RCEL; ASX: AVH) (“AVITA Medical”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin res
Read more →RCELAVITA Medical, Inc. Announces Proposed Public Offering of Common Stock
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 24, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (Nasdaq: RCEL; ASX: AVH) (“AVITA Medical”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin res
Read more →RCELAVITA MEDICAL
AVITA MEDICAL, INC. ANNOUNCES PRICING OF ITS PUBLIC OFFERING OF VALENCIA, Calif., Feb. 24, 2021 and MELBOURNE, Australia, Feb. 25, 2021 AVITA Medical, Inc. (Nasdaq: RCEL; ASX: AVH) ( AVITA Medical ), a regenerative medicine company that is developing and commercializing a techn
Read more →RCELAVITA Medical Reports Full Second Quarter 2021 Financial Results
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 11, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration
Read more →RCELAVITA Medical to Present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 03, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multi
Read more →RCELAVITA Medical to Announce Fiscal Second Quarter 2021 Financial Results
VALENCIA, Calif. and MELBOURNE, Australia, Jan. 28, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multi
Read more →RCELAVITA Medical Announces Preliminary Fiscal Second Quarter 2021 Results
VALENCIA, Calif. and MELBOURNE, Australia, Jan. 12, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multi
Read more →RCELASX/News Release AVITA Medical Announces Preliminary Fiscal Second Quarter 2021 Results Valencia, Calif. and
AVITA Medical Announces Preliminary Fiscal Second Quarter 2021 Results Valencia, Calif. and MELBOURNE, Australia, January 12, 2021 (GLOBE NEWSWIRE) AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology
Read more →RCELAVITA Medical to Present at the J.P. Morgan 39th Annual Healthcare Conference
VALENCIA, Calif. and MELBOURNE, Australia, Dec. 28, 2020 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multi
Read more →RCELAVITA Therapeutics Appoints Kathy McGee as Chief Operating Officer VALENCIA, Calif , USA, and MELBOURNE, Australia, December 1 2020 AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that i
AVITA Therapeutics Appoints Kathy McGee as Chief Operating Officer VALENCIA, Calif, USA, and MELBOURNE, Australia, December 1 2020 AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that
Read more →RCELAVITA Therapeutics to Participate at the Piper Sandler 32nd Annual Virtual Healthcare Conference
VALENCIA, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, anno
Read more →RCELAVITA Therapeutics Reports First Quarter 2021 Financial Results
VALENCIA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, toda
Read more →RCELAVITA Therapeutics, Inc.: Results of 2020 Annual Meeting of Shareholders
VALENCIA, Calif. and MELBOURNE, Australia, Nov. 10, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restor
Read more →RCELAVITA Therapeutics and the Houston Methodist Research Institute Enter into Collaboration to Explore Novel Approaches for Skin Rejuvenation
AVITA Therapeutics and the Houston Methodist Research Institute Enter into Collaboration to Explore Novel Approaches for Preclinical research will pair AVITA Therapeutics Spray-On Skin Cells with Houston Methodist Research Institute s technologies to reverse cellular aging AVIT
Read more →RCELAVITA Therapeutics, Inc. Announces Executive Change
VALENCIA, Calif. and MELBOURNE, Australia, Nov. 05, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for
Read more →RCELAVITA Therapeutics, Inc. Announces Executive Change Valencia, Calif, USA
AVITA Therapeutics, Inc. Announces Executive Change Valencia, Calif, USA, November 5, 2020 / Melbourne, Australia, November 6, 2020 AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform th
Read more →RCELAVITA THERAPEUTICS, INC. ANNOUNCES CORRECTION OF TIME FOR THE ADJOURNED 2020 ANNUAL STOCKHOLDER MEETING Valencia, Calif, USA
AVITA THERAPEUTICS, INC. ANNOUNCES CORRECTION OF TIME FOR THE Valencia, Calif, USA, November 4, 2020/Melbourne, November 5, 2020 AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that e
Read more →RCELAVITA Therapeutics Announces Date Change for First Quarter 2021 Earnings Release and Conference Call
VALENCIA, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, anno
Read more →RCELAVITA Therapeutics, Inc. Announces Adjournment of 2020 Annual Stockholder Meeting
AVITA Therapeutics, Inc. Announces Adjournment of 2020 Annual Stockholder Meeting VALENCIA, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that
Read more →RCELAVITA Therapeutics to Participate in Upcoming Investor Conferences
VALENCIA, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, anno
Read more →RCELAVITA Therapeutics to Announce First Quarter 2021 Financial Results
VALENCIA, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, anno
Read more →RCELShelf Registration Statement Filed with SEC Valencia, Calif, USA, and Melbourne, Australia
Shelf Registration Statement Filed with SEC Valencia, Calif, USA, and Melbourne, Australia, October 12, 2020 AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH) (the Company ) advises that it has filed a shelf registration statement on Form S-3 with the United States Securities an
Read more →RCELAppendix 4E Preliminary Final Report 30 June 2020 AVITA THERAPEUTICS, INC. ARBN 641 288 155 Results for announcement to the market (In thousands, except net tangible asset backing per ordinary security) Movement June 202
Preliminary Final Report Results for announcement to the market (In thousands, except net tangible asset backing per ordinary security) Movement June 2020 June 2019 Financial Results USD USD Sale of goods Up 161% 14,263 5,474 Other income Down 26% 4,612
Read more →RCELAVITA Therapeutics Provides Company Update and Revised Corporate Presentation Valencia, Calif., USA, and Melbourne, Australia
AVITA Therapeutics Provides Company Update and Revised Corporate Presentation Valencia, Calif., USA, and Melbourne, Australia, August 26, 2020 AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology
Read more →RCELBARDA to Initiate Procurement of the RECELL System for Emergency Response Preparedness Valencia, California, USA, and Melbourne, Australia
BARDA to Initiate Procurement of the RECELL System for Emergency Response Preparedness Valencia, California, USA, and Melbourne, Australia, July 13, 2020: AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a
Read more →RCELAVITA Therapeutics Provides Company Update and Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2020 Valencia, Calif., USA, and Melbourne, Australia
AVITA Therapeutics Provides Company Update and Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2020 Valencia, Calif., USA, and Melbourne, Australia, July 9, 2020 AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is deve
Read more →RCELASX/News Release AVITA Medical Limited Proposed redomiciliation to the United States of America Court approves scheme of arrangement Valencia, Calif., USA, and Melbourne, Australia, 22 June 2020: AVITA Medical Limited AC
AVITA Medical Limited Proposed redomiciliation to the United States of America Court approves scheme of arrangement Valencia, Calif., USA, and Melbourne, Australia, 22 June 2020: AVITA Medical Limited ACN 058 466 523 (Company) is pleased to announce that the Federal Court of
Read more →RCELASX/News Release AVITA Medical Limited Proposed redomiciliation to the United States of America Chair s address to Scheme Meeting Valencia, Calif., USA, and Melbourne, Australia, 15 June 2020: In accordance with ASX List
AVITA Medical Limited Proposed redomiciliation to the United States of America Chair s address to Scheme Meeting Valencia, Calif., USA, and Melbourne, Australia, 15 June 2020: In accordance with ASX Listing Rule 3.13.3, AVITA Medical Limited ACN 058 466 523 (Company) is pleas
Read more →RCELASX/News Release AVITA Medical Limited Proposed redomiciliation to the United States of America - Scheme Meeting on Monday, 15 June 2020 at 9.00am (AEST) Valencia, Calif., USA, and Melbourne, Australia, 10 June 2020: AVI
AVITA Medical Limited Proposed redomiciliation to the United States of America - Scheme Meeting on Monday, 15 June 2020 at 9.00am (AEST) Valencia, Calif., USA, and Melbourne, Australia, 10 June 2020: AVITA Medical Limited ACN 058 466 523 (Company) is pleased to confirm that t
Read more →RCELAVITA Medical Limited Proposed redomiciliation to the United States of America registration of Scheme Booklet with ASIC and financial reporting relief granted by ASIC Valencia, Calif., USA, and Melbourne, Australia, 12 M
AVITA Medical Limited Proposed redomiciliation to the United States of America registration of Scheme Booklet with ASIC and financial reporting relief granted by ASIC Valencia, Calif., USA, and Melbourne, Australia, 12 May 2020: AVITA Medical Limited (Company) (ASX:AVH, NASDA
Read more →RCELASX/News Release AVITA Medical Limited Proposed redomiciliation to the United States of America Federal Court of Australia orders convening of Scheme Meeting Valencia, Calif., USA, and Melbourne, Australia, 11 May 2020 :
AVITA Medical Limited Proposed redomiciliation to the United States of America Federal Court of Australia orders convening of Scheme Meeting Valencia, Calif., USA, and Melbourne, Australia, 11 May 2020: AVITA Medical Limited (Company) (ASX:AVH, NASDAQ:RCEL) is pleased to anno
Read more →RCELASX/News Release AVITA Medical Reports Third Quarter Fiscal 2020 Financial Results and Company Update U.S. RECELL System product sales of A$5.81M for fiscal third quarter Valencia, Calif., USA, and Melbourne, Australia,
AVITA Medical Reports Third Quarter Fiscal 2020 Financial Results and Company Update U.S. RECELL System product sales of A$5.81M for fiscal third quarter Valencia, Calif., USA, and Melbourne, Australia, 29 April 2020 AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerat
Read more →RCELASX/News Release AVITA Medical Announces Intention to Redomicile to the United States of America Intention to establish primary listing on NASDAQ with continued (secondary) listing on ASX Valencia, Calif., USA, and Melbo
AVITA Medical Announces Intention to Redomicile to the United States of America Intention to establish primary listing on NASDAQ with continued (secondary) listing on ASX Valencia, Calif., USA, and Melbourne, Australia, 20 April 2020: AVITA Medical Limited (Company) (ASX: AV
Read more →RCELASX/News Release AVITA Medical Provides Preliminary Top Line Results for the Third Quarter and COVID-19 Update Valencia, Calif., USA, and Melbourne, Australia, 6 April 2020 AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL),
AVITA Medical Provides Preliminary Top Line Results for the Third Quarter and COVID-19 Update Valencia, Calif., USA, and Melbourne, Australia, 6 April 2020 AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to
Read more →RCELASX/News Release AVITA Medical Half-Year Financial Report for Fiscal 2020 Valencia, Calif., USA, and Melbourne, Australia, 19 February 2020 AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company
AVITA Medical Half-Year Financial Report for Fiscal 2020 Valencia, Calif., USA, and Melbourne, Australia, 19 February 2020 AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in the
Read more →RCELASX/News Release AVITA Medical Reports Second Quarter Fiscal 2020 Financial Results and Company Update U.S. RECELL System product sales of A$4.66M for fiscal second quarter Valencia, Calif., USA, and Melbourne, Australia
AVITA Medical Reports Second Quarter Fiscal 2020 Financial Results and Company Update U.S. RECELL System product sales of A$4.66M for fiscal second quarter Valencia, Calif., USA, and Melbourne, Australia, 31 January 2020 AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regene
Read more →RCELDecember 2019 Registered Office: Avita Medical Limited c/o Mertons Corporate Services Pty Ltd Level 7 330 Collins Street Melbourne VIC 3000, Australia ABN 28 058 466 523 The Manager ASX Market Announcements Australian Se
Australian Securities Exchange At the 2019 Annual General Meeting, dated 26 November, 2019, shareholders approved the allotment of various restricted stock units to the Company s Chief Executive Officer, Dr. Michael Perry (see the Notice of Meeting distributed to shareholders o
Read more →RCELASX/News Release AVITA Medical Names David McIntyre as Chief Financial Officer Appointment Enhances Executive Leadership Team as AVITA Medical Broadens Access to Investors and Continues Growth Trajectory Interim CFO Tim
AVITA Medical Names David McIntyre as Chief Financial Officer Valencia, Calif., USA, and Melbourne, Australia, 18 November 2019 AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therap
Read more →RCELASX/News Release AVITA Medical Announces Institutional Placement of A$120.0 Million to Support Commercial Growth and Pipeline Development Valencia, Calif., USA, and Melbourne, Australia, 13 November 2019 AVITA Medical (A
AVITA Medical Announces Institutional Placement of A$120.0 Million to Support Commercial Growth and Pipeline Valencia, Calif., USA, and Melbourne, Australia, 13 November 2019 AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform posi
Read more →RCELASX/News Release AVITA Medical Reports First Quarter Fiscal 2020 Financial Results and Company Update U.S. RECELL System product sales of A$4.6M for fiscal first quarter, 60% growth quarter-over-quarter Over half of all
AVITA Medical Reports First Quarter Fiscal 2020 Financial Results and Company Update Valencia, Calif., USA, and Melbourne, Australia, 31 October 2019 AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet
Read more →RCELAVITA MEDICAL LIMITED ACN 058 466 523 NOTICE OF 2019 ANNUAL GENERAL MEETING Notice is given that the Meeting will be held at: TIME : 11.00am (Melbourne time) DATE : 26 November 2019 PLACE : Offices of K & L Gates, Level
AVITA MEDICAL LIMITED NOTICE OF 2019 ANNUAL GENERAL MEETING Notice is given that the Meeting will be TIME: 11.00am (Melbourne time) DATE: 26 November 2019 K & L Gates, Level 25, 525 Collins Street, Melbourne, Victoria The business of the Meeting affects your shareholding an
Read more →RCELCONTENTS Corporate Information 3 Letter from the Chairman and CEO 4-5 Directors Report 6-24 Auditor s Independence Declaration 25 Consolidated Statement of Profit or Loss and Other Comprehensive Income 26 Consolidated St
Corporate Information 3 Letter from the Chairman and CEO 4-5 Directors Report 6-24 Auditor s Independence Declaration 25 Consolidated Statement of Profit or Loss and Other Comprehensive Income 26 Consolidated Statement of Financial Position 27 Consolidated State
Read more →RCELAVITA MEDICAL LIMITED A.B.N. 28 058 466 523 FULL FINANCIAL REPORT For the year ended 30 June 2019 1 Corporate Information ABN 28 058 466 523 This annual report covers the consolidated entity comprising Avita Medical Limi
AVITA MEDICAL LIMITED A.B.N. 28 058 466 523 FULL FINANCIAL REPORT For the year ended 30 June 2019 Corporate Information This annual report covers the consolidated entity comprising Avita Medical Limited (the Parent Company) and its controlled subsidiaries (the Company). The
Read more →Competitive Position
How RCEL ranks across every disease it competes inCompetitive Position is a premium feature
See how RCEL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial